The estimated Net Worth of Patrick Trojer is at least $1.65 Million dollars as of 6 May 2020. Mr. Trojer owns over 10,000 units of Constellation Pharmaceuticals Inc stock worth over $339,900 and over the last 6 years he sold CNST stock worth over $1,311,158. In addition, he makes $0 as Chief Scientific Officer at Constellation Pharmaceuticals Inc.
Patrick has made over 4 trades of the Constellation Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CNST stock worth $70,400 on 6 May 2020.
The largest trade he's ever made was selling 46,142 units of Constellation Pharmaceuticals Inc stock on 6 November 2019 worth over $1,156,780. On average, Patrick trades about 7,520 units every 22 days since 2018. As of 6 May 2020 he still owns at least 10,000 units of Constellation Pharmaceuticals Inc stock.
You can see the complete history of Mr. Trojer stock trades at the bottom of the page.
Patrick Trojer Ph.D. serves as Chief Scientific Officer of the Company. Prior to that, Dr. Trojer served as our senior vice president, EZH2 franchise and head of translational sciences since June 2017. Dr. Trojer joined us as a founding scientist in 2008. Dr. Trojer has served in various positions at our company, including as vice president, head of research from October 2015 to June 2017, executive director, head of biology from October 2014 to October 2015, senior director, head of biology from March 2012 to October 2014, director, head of biology from 2010 to March 2012, senior scientist from 2009 to 2010 and scientist from 2008 to 2009. Dr. Trojer completed his postdoctoral studies at NYU Medical School, prior to which he received a Ph.D. in protein biochemistry and molecular biology and an M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.
Patrick Trojer is 47, he's been the Chief Scientific Officer of Constellation Pharmaceuticals Inc since 2018. There are 9 older and 1 younger executives at Constellation Pharmaceuticals Inc. The oldest executive at Constellation Pharmaceuticals Inc is James Audia, 64, who is the Director.
Patrick's mailing address filed with the SEC is C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE, MA, 02142.
Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo..., and Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include: